HUTCHMED (NASDAQ:HCM) Shares Gap Up – Here’s Why

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) gapped up prior to trading on Monday . The stock had previously closed at $13.81, but opened at $14.40. HUTCHMED shares last traded at $14.2460, with a volume of 15,630 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Bank of America reduced their price objective on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $16.88.

HUTCHMED Stock Performance

The business’s 50-day moving average is $14.59 and its two-hundred day moving average is $14.77. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83.

HUTCHMED (NASDAQ:HCM) last issued its quarterly earnings data on Friday, March 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The company had revenue of $135.42 million for the quarter, compared to analysts’ expectations of $290.50 million. On average, analysts forecast that HUTCHMED will post 0.16 EPS for the current fiscal year.

Institutional Trading of HUTCHMED

Large investors have recently made changes to their positions in the company. Jane Street Group LLC raised its stake in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after buying an additional 124,771 shares during the period. UBS Group AG grew its stake in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after acquiring an additional 72,614 shares during the period. Amundi increased its holdings in shares of HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after acquiring an additional 65,898 shares in the last quarter. M&G PLC increased its holdings in shares of HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after acquiring an additional 54,601 shares in the last quarter. Finally, Tema Etfs LLC acquired a new stake in shares of HUTCHMED during the second quarter worth about $641,000. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.